Molecular pathways: Induction of polyploidy as a novel differentiation therapy for leukemia

Clinical Cancer Research

Volumn 19, Issue 22, 2013, Pages 6084-6088

  Krause, Diane S ^a   Crispino, John D ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 DIHYDRO 2 OXO 3 (4,5,6,7 TETRAHYDRO 1H INDOL 2 YLMETHYLENE) 1H INDOLE 5 SULFONIC ACID DIMETHYLAMIDE; ALISERTIB; ANTINEOPLASTIC AGENT; DIMETHYLFASUDIL; PHOSPHOTRANSFERASE INHIBITOR; UNCLASSIFIED DRUG;

ACUTE MEGAKARYOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CARCINOGENESIS; CELL CYCLE REGULATION; DOSE RESPONSE; DRUG DESIGN; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG TARGETING; HUMAN; LONG TERM SURVIVAL; MEGAKARYOCYTE; MITOSIS; MYELODYSPLASTIC SYNDROME; NONHUMAN; POLYPLOIDY; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME;

ANTINEOPLASTIC AGENTS; AURORA KINASE A; AZEPINES; CELL DIFFERENTIATION; CELL LINE, TUMOR; HUMANS; LEUKEMIA, MEGAKARYOBLASTIC, ACUTE; LEUKEMIA, PROMYELOCYTIC, ACUTE; MEGAKARYOCYTES; MITOSIS; POLYPLOIDY; PRIMARY MYELOFIBROSIS; PROTEIN KINASE INHIBITORS; PYRIMIDINES; TRETINOIN;

EID: 84888093257     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-2604     Document Type: Article

References (49)

1. Battinelli EM, Hartwig JH, Italiano JE Jr. Delivering new insight into the biology of megakaryopoiesis and thrombopoiesis. Curr Opin Hematol 2007;14:419-26. (Pubitemid 47457630)
2. Raslova H, Roy L, Vourc'h C, Le Couedic JP, Brison O, Metivier D, et al. Megakaryocyte polyploidization is associated with a functional gene amplification. Blood 2003;101:541-4. (Pubitemid 36077575)
3. Raslova H, Kauffmann A, Sekkai D, Ripoche H, Larbret F, Robert T, et al. Interrelation between polyploidization and megakaryocyte differentiation: a gene profiling approach. Blood 2007;109:3225-34. (Pubitemid 46572507)
4. Narumiya S, Yasuda S. Rho GTPases in animal cell mitosis. Curr Opin Cell Biol 2006;18:199-205. (Pubitemid 43375889)
5. Bement WM, Benink HA, von Dassow G. A microtubule-dependent zone of active RhoA during cleavage plane specification. J Cell Biol 2005;170:91-101. (Pubitemid 40994099)
6. Madaule P, Eda M, Watanabe N, Fujisawa K, Matsuoka T, Bito H, et al. Role of citron kinase as a target of the small GTPase Rho in cytokinesis. Nature 1998;394:491-4. (Pubitemid 28373961)
7. Yasui Y, Amano M, Nagata K, Inagaki N, Nakamura H, Saya H, et al. Roles of Rho-associated kinase in cytokinesis; mutations in Rho-associated kinase phosphorylation sites impair cytokinetic segregation of glial filaments. J Cell Biol 1998;143:1249-58. (Pubitemid 28559826)
8. Kosako H, Goto H, Yanagida M, Matsuzawa K, Fujita M, Tomono Y, et al. Specific accumulation of Rho-associated kinase at the cleavage furrow during cytokinesis: cleavage furrow-specific phosphorylation of intermediate filaments. Oncogene 1999;18:2783-8. (Pubitemid 29237668)
9. Kosako H, Yoshida T, Matsumura F, Ishizaki T, Narumiya S, Inagaki M. Rho-kinase/ROCK is involved in cytokinesis through the phosphorylation of myosin light chain and not ezrin/radixin/moesin proteins at the cleavage furrow. Oncogene 2000;19:6059-64. (Pubitemid 32039380)
10. Tolliday N, Ver Plank L, Li R. Rho1 directs formin-mediated actin ring assembly during budding yeast cytokinesis. Curr Biol 2002;12:1864-70. (Pubitemid 35273908)
11. Papadantonakis N, Makitalo M, McCrann DJ, Liu K, Nguyen HG, Martin G, et al. Direct visualization of the endomitotic cell cycle in living megakaryocytes: differential patterns in low and high ploidy cells. Cell Cycle 2008;7:2352-6.
12. Lordier L, Jalil A, Aurade F, Larbret F, Larghero J, Debili N, et al. Megakaryocyte endomitosis is a failure of late cytokinesis related to defects in the contractile ring and Rho/Rock signaling. Blood 2008;112:3164-74.
13. Geddis AE, Fox NE, Tkachenko E, Kaushansky K. Endomitotic megakaryocytes that form a bipolar spindle exhibit cleavage furrow ingression followed by furrow regression. Cell Cycle 2007;6:455-60. (Pubitemid 46393450)
14. Leysi-Derilou Y, Robert A, Duchesne C, Garnier A, Boyer L, Pineault N. Polyploid megakaryocytes can complete cytokinesis. Cell Cycle 2010;9:2589-99.
15. Geddis AE, Kaushansky K. Endomitotic megakaryocytes form a midzone in anaphase but have a deficiency in cleavage furrow formation. Cell Cycle 2006;5:538-45. (Pubitemid 43340533)
16. Etienne-Manneville S, Hall A. Rho GTPases in cell biology. Nature 2002;420:629-35. (Pubitemid 36764489)
17. Rossman KL, der CJ, Sondek J. GEF means go: turning on RHO GTPases with guanine nucleotide-exchange factors. Nat Rev Mol Cell Biol 2005;6:167-80. (Pubitemid 40215811)
18. Petronczki M, Glotzer M, Kraut N, Peters JM. Polo-like kinase 1 triggers the initiation of cytokinesis in human cells by promoting recruitment of the RhoGEF Ect2 to the central spindle. Dev Cell 2007;12:713-25. (Pubitemid 46667747)
19. Yuce O, Piekny A, Glotzer M. An ECT2-centralspindlin complex regulates the localization and function of RhoA. J Cell Biol 2005;170:571-82. (Pubitemid 41186932)
20. Fields AP, Justilien V. The guanine nucleotide exchange factor (GEF) Ect2 is an oncogene in human cancer. Adv Enzyme Regul 2010;50:190-200.
21. Iyoda M, Kasamatsu A, Ishigami T, Nakashima D, Endo-Sakamoto Y, Ogawara K, et al. Epithelial cell transforming sequence 2 in human oral cancer. PLoS One 2010;5:e14082.
22. Birkenfeld J, Nalbant P, Bohl BP, Pertz O, Hahn KM, Bokoch GM. GEF-H1 modulates localized RhoA activation during cytokinesis under the control of mitotic kinases. Dev Cell 2007;12:699-712. (Pubitemid 46671149)
23. Melnick A, Licht JD. Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 1999;93:3167-215. (Pubitemid 29220886)
24. Lannutti BJ, Blake N, Gandhi MJ, Reems JA, Drachman JG. Induction of polyploidization in leukemic cell lines and primary bone marrow by Src kinase inhibitor SU6656. Blood 2005;105:3875-8. (Pubitemid 40656131)
25. Wen Q, Goldenson B, Silver SJ, Schenone M, Dancik V, Huang Z, et al. Identification of regulators of polyploidization presents therapeutic targets for treatment of AMKL. Cell 2012;150:575-89.
26. Manfredi MG, Ecsedy JA, Chakravarty A, Silverman L, Zhang M, Hoar KM, et al. Characterization of Alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacodynamic assays. Clin Cancer Res 2011;17:7614-24.
27. Thiollier C, Lopez CK, Gerby B, Ignacimouttou C, Poglio S, Duffourd Y, et al. Characterization of novel genomic alterations and therapeutic approaches using acute megakaryoblastic leukemia xenograft models. J Exp Med 2012;209:2017-31.
28. Lange B. The management of neoplastic disorders of haematopoiesis in children with Down's syndrome. Br J Haematol 2000;110:512-24.
29. Zipursky A, Peeters M, Poon A. Megakaryoblastic leukemia and Down's syndrome: a review. Pediatr Hematol Oncol 1987;4:211-30.
30. Wechsler J, Greene M, McDevitt MA, Anastasi J, Karp JE, Le Beau MM, et al. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet 2002;32:148-52. (Pubitemid 34977210)
31. Lion T, Haas OA, Harbott J, Bannier E, Ritterbach J, Jankovic M, et al. The translocation t (1;22) (p13;q13) is a nonrandom marker specifically associated with acute megakaryocytic leukemia in young children. Blood 1992;79:3325-30.
32. Mercher T, Coniat MB, Monni R, Mauchauffe M, Nguyen Khac F, Gressin L, et al. Involvement of a human gene related to the Drosophila spen gene in the recurrent t (1;22) translocation of acute megakaryocytic leukemia. Proc Natl Acad Sci U S A 2001;98:5776-9. (Pubitemid 32435718)
33. Ma Z, Morris SW, Valentine V, Li M, Herbrick JA, Cui X, et al. Fusion of two novel genes, RBM15 and MKL1, in the t (1;22) (p13;q13) of acute megakaryoblastic leukemia. Nat Genet 2001;28:220-1. (Pubitemid 32626023)
34. Gruber TA, Larson Gedman A, Zhang J, Koss CS, Marada S, Ta HQ, et al. An Inv (16) (p13.3q24.3)-encoded CBFA2T3-GLIS2 fusion protein defines an aggressive subtype of pediatric acute megakaryoblastic leukemia. Cancer Cell 2012;22:683-97.
35. de Rooij JD, Hollink IH, Arentsen-Peters ST, van Galen JF, Berna Beverloo H, Baruchel A, et al. NUP98/JARID1A is a novel recurrent abnormality in pediatric acute megakaryoblastic leukemia with a distinct HOX gene expression pattern. Leukemia. 2013 Mar. 27. [Epub ahead of print].
36. Walters DK, Mercher T, Gu TL, O'Hare T, Tyner JW, Loriaux M, et al. Activating alleles of JAK3 in acute megakaryoblastic leukemia. Cancer Cell 2006;10:65-75.
37. Malinge S, Ragu C, Della-Valle V, Pisani D, Constantinescu SN, Perez C, et al. Activating mutations in human acute megakaryoblastic leukemia. Blood 2008;112:4220-6.
38. Hussein K, Bock O, Theophile K, Schulz-Bischof K, Porwit A, Schlue J, et al. MPLW515L mutation in acute megakaryoblastic leukaemia. Leukemia 2009;23:852-5.
39. Sorrell AD, Alonzo TA, Hilden JM, Gerbing RB, Loew TW, Hathaway L, et al. Favorable survival maintained in children who have myeloid leukemia associated with Down syndrome using reduced-dose chemotherapy on Children's Oncology Group trial A2971: a report from the Children's Oncology Group. Cancer 2012;118:4806-14.
40. O'Brien MM, Taub JW, Chang MN, Massey GV, Stine KC, Raimondi SC, et al. Cardiomyopathy in children with Down syndrome treated for acute myeloid leukemia: a report from the Children's Oncology Group Study POG 9421. J Clin Oncol 2008;26:414-20. (Pubitemid 351171693)
41. O'Brien MM, Cao X, Pounds S, Dahl GV, Raimondi SC, Lacayo NJ, et al. Prognostic features in acute megakaryoblastic leukemia in children without Down syndrome: a report from the AML02 multicenter trial and the Children's Oncology Group Study POG 9421. Leukemia 2013;27:731-4.
42. Bernstein J, Dastugue N, Haas OA, Harbott J, Heerema NA, Huret JL, et al. Nineteen cases of the t (1;22) (p13;q13) acute megakaryblastic leukaemia of infants/children and a review of 39 cases: report from a t (1;22) study group. Leukemia 2000;14:216-8. (Pubitemid 30068396)
43. Barnard DR, Alonzo TA, Gerbing RB, Lange B, Woods WG. Comparison of childhood myelodysplastic syndrome, AML FAB M6 or M7, CCG 2891: Report from the Children's Oncology Group. Pediatr Blood Cancer 2007;49:17-22. (Pubitemid 46850650)
44. Athale UH, Razzouk BI, Raimondi SC, Tong X, Behm FG, Head DR, et al. Biology and outcome of childhood acute megakaryoblastic leukemia: a single institution's experience. Blood 2001;97:3727-32.
45. Tallman MS, Neuberg D, Bennett JM, Francois CJ, Paietta E, Wiernik PH, et al. Acute megakaryocytic leukemia: the Eastern Cooperative Oncology Group experience. Blood 2000;96:2405-11.
46. Pagano L, Pulsoni A, Vignetti M, Mele L, Fianchi L, Petti MC, et al. Acute megakaryoblastic leukemia: experience of GIMEMA trials. Leukemia 2002;16:1622-6.
47. Goldberg SL, Fenaux P, Craig MD, Gyan E, Lister J, Kassis J, et al. Phase 2 study of MLN8237, an investigational aurora A kinase (AAK) inhibitor in patients with acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS). Blood ASH Annual Meeting abstracts 2010;116:3273.
48. Gorgun G, Calabrese E, Hideshima T, Ecsedy J, Perrone G, Mani M, et al. A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma. Blood 2010;115:5202-13.
49. Sehdev V, Peng D, Soutto M, Washington MK, Revetta F, Ecsedy J, et al. The aurora kinase A inhibitor MLN8237 enhances cisplatininduced cell death in esophageal adenocarcinoma cells. Mol Cancer Ther 2012;11:763-74.